Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259010 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02259010 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT02259010, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.
Interventions
- DRUG Itraconazole
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-10-22 |
| Est. Completion | 2016-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02259010
The ClinicalTrials.gov registry entry for NCT02259010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT02259010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02259010 about?
NCT02259010 is a clinical study titled "A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma". This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.
What is the current status of trial NCT02259010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-10-22. Estimated completion is 2016-10-21.
What interventions are being tested in trial NCT02259010?
The interventions under investigation include: Itraconazole (DRUG), Alisertib (DRUG).
Who is sponsoring clinical trial NCT02259010?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.